Odronextamab (cd20xcd3) demonstrates high and durable complete response rate among patients with relapsed/refractory follicular lymphoma in pivotal phase 2 trial

First phase 2 data presented at ash showed an 82% response rate in patients with grades 1 to 3a disease, with 75% of the overall population achieving a complete response 20-month median progression-free survival, with median overall survival not reached data will form the basis of regulatory submissions planned for 2023 tarrytown, n.y. , dec. 12, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive first data from a cohort of a pivotal phase 2 trial evaluating investigational odronextamab in patients with heavily pre-treated, relapsed/refractory (r/r) follicular lymphoma (fl) grades 1 to 3a.
REGN Ratings Summary
REGN Quant Ranking